Tuesday, October 07, 2025 3:23:15 PM
The paid pump crew knows that, but their job is to build false expectations to string along more bag holders.
The IFR is a last resort and done on a case by case basis, led by physicians. No physician outside GBM is going to recommend this to their patients anyway. Either way, not many physicians will have the time and resources to do such paperwork on an ongoing basis and wait for the bureaucrats to approve. And importantly, the available fund in IFR is going to be extremely limited. Perhaps one or two dozen patients per year for DCVAx-L under IFR if they are lucky would be my guess.
That’s why without reimbursement approval this is never going above $15M in annual revenue. The fact that they haven’t submitted reimbursement evidence 5 years since data lock tells us that they are not confident, and therefore will continue to stall this for another year or two. Otherwise, no reason to not submit the evidence last year and have that be done in parallel.
The IFR is a last resort and done on a case by case basis, led by physicians. No physician outside GBM is going to recommend this to their patients anyway. Either way, not many physicians will have the time and resources to do such paperwork on an ongoing basis and wait for the bureaucrats to approve. And importantly, the available fund in IFR is going to be extremely limited. Perhaps one or two dozen patients per year for DCVAx-L under IFR if they are lucky would be my guess.
That’s why without reimbursement approval this is never going above $15M in annual revenue. The fact that they haven’t submitted reimbursement evidence 5 years since data lock tells us that they are not confident, and therefore will continue to stall this for another year or two. Otherwise, no reason to not submit the evidence last year and have that be done in parallel.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
